FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileTranslational Development Acquisition Corp.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
TDAC
Translational Development Acquisition Corp. Stock AnalysisComprehensive stock analysis for Translational Development Acquisition Corp. (TDAC) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisTDAC
TDAC
Translational Development Acquisition Corp.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
TDAC
  1. Home
  2. Stocks
  3. Translational Development Acquisition Corp.

Translational Development Acquisition Corp.

🇺🇸TDAC•NASDAQ

Translational Development Acquisition Corp.

🇺🇸TDAC•NASDAQ
Market cap
$267.48M
Sentiment

Your view on TDAC

Mkt Cap
$267.48M
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Translational Development Acquisition Corp.

Industry
Shell Companies
Sector
Financial Services
CEO
Michael Hoffman
Headquarters
52 E. 83rd Street, New York City, NY, US
Industry
Shell Companies
Sector
Financial Services
CEO
Michael Hoffman
Headquarters
52 E. 83rd Street, New York City, NY, US
Description

Translational Development Acquisition Corp., founded in 2022 and headquartered in New York, New York, currently conducts no significant business operations. Its primary goal is to complete a business combination, such as a merger, amalgamation, share exchange, asset acquisition, share purchase, or reorganization, with one or more companies.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Translational Development Acquisition Corp. from FRC's valuation model, read against the market price. TDAC last traded at $10.86; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Translational Development Acquisition Corp.. Starting points for Translational Development Acquisition Corp.: EPS -$0.37, beta 0.01 — an Shell Companies name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Translational Development Acquisition Corp.. Translational Development Acquisition Corp. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Translational Development Acquisition Corp.. Trailing twelve-month EPS for Translational Development Acquisition Corp. stands at -$0.37. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 17, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Analyst Ratings

Buy1 rating
  • Strong Buy0
  • Buy1
  • Hold0
  • Sell0
  • Strong Sell0
Recent analyst actions1 rating and price-target change, latest Sep 21, 2021 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 17, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Translational Development Acquisition Corp.. Translational Development Acquisition Corp. has reported as a listed company since 2025. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold TDAC18 companies
Compare TDAC with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • CEPOCantor Equity Partners I, Inc. Class A Ordinary SharesShell Companies$222M
  • FACTFACT II Acquisition CorpShell Companies$265M
  • HCMAHCM Acquisition CorpShell Companies$136M
  • MACIMelar Acquisition Corp. IShell Companies$217M
  • NTWONewbury Street II Acquisition CorpShell Companies$195M
  • SZZLSizzle Acquisition Corp. IIShell Companies$249M

More Shell Companies companies

  • GIXXUGigCapital9 Corp. UnitsNASDAQ$261M
  • GLBBGlobal Quest Ltd.OTC$1,005
  • GLEDGalaxyEdge Acquisition CorporationNYSE$163M
  • GLRIGlori Energy Inc.OTC$6,474
  • GMZPGEMZ CorporationOTC$222,599
  • GPACGeneral Purpose Acquisition Corp.NASDAQ$240M
  • GPACUGeneral Purpose Acquisition Corp.NASDAQ$241M
  • GPATGP-Act III Acquisition Corp.NASDAQ$176M
  • GPATUGP-Act III Acquisition Corp.NASDAQ$392M
  • GPATWGP-Act III Acquisition Corp.NASDAQ$275M
  • GPLBGreen Planet Bioengineering Co LtdOTC$342,109
  • GRGGGreen For Energy, Inc.OTC
Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Translational Development Acquisition Corp., and how their positions are changing. At a $267.5M market value, institutional positions materially move Translational Development Acquisition Corp.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Translational Development Acquisition Corp. executives and directors. Shares of Translational Development Acquisition Corp. have traded between $10.32 and $10.90 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Translational Development Acquisition Corp.. Coverage tracks Translational Development Acquisition Corp. within Shell Companies (Financial Services). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Translational Development Acquisition Corp.

TDAC Analysis
Fair
Past2
Growth2
Health5
Profit1
Value1

News

Latest Market News